GLAUKOS CORP (GKOS)
Health Care · Ophthalmic medical devices and pharmaceuticals · NYSE
Glaukos is an ophthalmic medical device and pharmaceutical innovator pioneering minimally invasive glaucoma surgery and dropless therapies for eye disease.
What GLAUKOS CORP does
Glaukos is an ophthalmic pharmaceutical and medical technology company developing novel, dropless platform therapies for glaucoma, corneal disorders, and retinal disease. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) devices, and has expanded its portfolio to include sustained-release pharmaceuticals like iDose TR for glaucoma treatment and Epioxa, an incision-free bio-activated therapy for keratoconus. The company also manufactures Photrexa, a first-generation corneal cross-linking therapy, and is advancing products for dry eye, refractive vision correction, and retinal diseases.
Themes: ["glaucoma surgical treatment","minimally invasive eye surgery","corneal disorders / keratoconus","sustained-release pharmaceuticals","corneal cross-linking","retinal disease treatment","dry eye disease","refractive vision correction","ophthalmology / eye care","medical devices and pharmaceuticals"]
Fundamentals
- Price$155.07 as of 2026-07-09 close
- Market cap$9.1B as of 2026-07-10
- 1-year return+48.1% as of 2026-07-09 close
- Net margin-34.3% as of 2026-07-10
- Gross margin+78.1% as of 2026-07-10
- ROE-26.5% as of 2026-07-10
- Debt / equity0.10 as of 2026-07-10
- Revenue growth (YoY)+36.3% as of 2026-07-10
- Revenue CAGR (3y)+21.5% SEC XBRL
- Beta0.76 as of 2026-07-10
Key risks (from latest filing)
["Company is currently unprofitable with net losses of $19.8 million in Q1 2026 and accumulated deficit of $952.9 million; significant operating expenses exceed gross margin contributions.","Dependency on successful commercialization of newer products (iDose TR, Epioxa) to drive future revenue growth; transition from legacy Photrexa to Epioxa carries execution risk.","Exposure to macroeconomic headwinds including inflation, supply chain disruptions, foreign exchange fluctuations, and geopolitical tensions (Middle East conflicts) that could impact manufacturing, logistics, and raw material costs."]
Competitors & peers
- Alcon
- Bausch Health Companies
- Allergan (part of AbbVie)
- Carl Zeiss Meditec
- Ellex Medical
- Haag-Streit
- Johnson & Johnson Vision
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.